Viral hepatitis

Progress and problems

Thomas W Kiernan, M. Ramgopal

Research output: Contribution to journalArticle

Abstract

The recognition of viral hepatitis has been facilitated by the use of serologic studies for types A, B and non A, non B. Viral hepatitis is transmitted through blood as indicated by studies in drug addicts, maternal-infant transmission and by close contact, with possible spread by saliva and tears. The course of viral hepatitis is best determined by using serum enzymes, followed by clearance studies of bile acids or dyes, once the enzymes return to normal. In patients with persisting clinical or biochemical abnormalities and subjects in which the nature of the disease is not known, a liver biopsy should be performed. Treatment of acute viral hepatitis and its complications is largely supportive. Special measures for evidence of liver failure have significantly reduced the mortality from fulminant hepatitis, and the use of immunosuppressive agents has decreased morbidity in chronic active hepatitis. Pooled gammaglobulin has varying amounts of antibodies to A, B and non A, non B viruses and may therefore be useful in prophylaxis. Viral B hepatitis is preventable by specific use of immune globulin preparations or specific vaccines now being used in clinical investigative studies.

Original languageEnglish (US)
Pages (from-to)611-619
Number of pages9
JournalMedical Clinics of North America
Volume63
Issue number3
DOIs
StatePublished - Jan 1 1979
Externally publishedYes

Fingerprint

Hepatitis
Hepatitis B
Cercopithecine Herpesvirus 1
Liver Failure
Enzymes
Chronic Hepatitis
Immunosuppressive Agents
Drug Users
Bile Acids and Salts
Tears
Saliva
Immunoglobulins
Coloring Agents
Vaccines
Mothers
Morbidity
Biopsy
Mortality
Antibodies
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Viral hepatitis : Progress and problems. / Kiernan, Thomas W; Ramgopal, M.

In: Medical Clinics of North America, Vol. 63, No. 3, 01.01.1979, p. 611-619.

Research output: Contribution to journalArticle

Kiernan, Thomas W ; Ramgopal, M. / Viral hepatitis : Progress and problems. In: Medical Clinics of North America. 1979 ; Vol. 63, No. 3. pp. 611-619.
@article{729d2b5d3a634bb6ac504c38632a8942,
title = "Viral hepatitis: Progress and problems",
abstract = "The recognition of viral hepatitis has been facilitated by the use of serologic studies for types A, B and non A, non B. Viral hepatitis is transmitted through blood as indicated by studies in drug addicts, maternal-infant transmission and by close contact, with possible spread by saliva and tears. The course of viral hepatitis is best determined by using serum enzymes, followed by clearance studies of bile acids or dyes, once the enzymes return to normal. In patients with persisting clinical or biochemical abnormalities and subjects in which the nature of the disease is not known, a liver biopsy should be performed. Treatment of acute viral hepatitis and its complications is largely supportive. Special measures for evidence of liver failure have significantly reduced the mortality from fulminant hepatitis, and the use of immunosuppressive agents has decreased morbidity in chronic active hepatitis. Pooled gammaglobulin has varying amounts of antibodies to A, B and non A, non B viruses and may therefore be useful in prophylaxis. Viral B hepatitis is preventable by specific use of immune globulin preparations or specific vaccines now being used in clinical investigative studies.",
author = "Kiernan, {Thomas W} and M. Ramgopal",
year = "1979",
month = "1",
day = "1",
doi = "10.1016/S0025-7125(16)31691-1",
language = "English (US)",
volume = "63",
pages = "611--619",
journal = "The Medical clinics of North America",
issn = "0025-7125",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Viral hepatitis

T2 - Progress and problems

AU - Kiernan, Thomas W

AU - Ramgopal, M.

PY - 1979/1/1

Y1 - 1979/1/1

N2 - The recognition of viral hepatitis has been facilitated by the use of serologic studies for types A, B and non A, non B. Viral hepatitis is transmitted through blood as indicated by studies in drug addicts, maternal-infant transmission and by close contact, with possible spread by saliva and tears. The course of viral hepatitis is best determined by using serum enzymes, followed by clearance studies of bile acids or dyes, once the enzymes return to normal. In patients with persisting clinical or biochemical abnormalities and subjects in which the nature of the disease is not known, a liver biopsy should be performed. Treatment of acute viral hepatitis and its complications is largely supportive. Special measures for evidence of liver failure have significantly reduced the mortality from fulminant hepatitis, and the use of immunosuppressive agents has decreased morbidity in chronic active hepatitis. Pooled gammaglobulin has varying amounts of antibodies to A, B and non A, non B viruses and may therefore be useful in prophylaxis. Viral B hepatitis is preventable by specific use of immune globulin preparations or specific vaccines now being used in clinical investigative studies.

AB - The recognition of viral hepatitis has been facilitated by the use of serologic studies for types A, B and non A, non B. Viral hepatitis is transmitted through blood as indicated by studies in drug addicts, maternal-infant transmission and by close contact, with possible spread by saliva and tears. The course of viral hepatitis is best determined by using serum enzymes, followed by clearance studies of bile acids or dyes, once the enzymes return to normal. In patients with persisting clinical or biochemical abnormalities and subjects in which the nature of the disease is not known, a liver biopsy should be performed. Treatment of acute viral hepatitis and its complications is largely supportive. Special measures for evidence of liver failure have significantly reduced the mortality from fulminant hepatitis, and the use of immunosuppressive agents has decreased morbidity in chronic active hepatitis. Pooled gammaglobulin has varying amounts of antibodies to A, B and non A, non B viruses and may therefore be useful in prophylaxis. Viral B hepatitis is preventable by specific use of immune globulin preparations or specific vaccines now being used in clinical investigative studies.

UR - http://www.scopus.com/inward/record.url?scp=0018777372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018777372&partnerID=8YFLogxK

U2 - 10.1016/S0025-7125(16)31691-1

DO - 10.1016/S0025-7125(16)31691-1

M3 - Article

VL - 63

SP - 611

EP - 619

JO - The Medical clinics of North America

JF - The Medical clinics of North America

SN - 0025-7125

IS - 3

ER -